Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2022-04-07 Proxy Solicitation & In…
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2022-04-07 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 4, 2022, by Vir Biotechnology, Inc. The content focuses on the appointment of a new Executive Vice President and Chief Operating Officer, detailing her background and the circumstances of her appointment. There is no financial data, earnings information, or report publication mentioned. The key item is Item 5.02, which relates to the departure or appointment of directors or certain officers. This matches the category for Board/Management Information (MANG). The document length is 5225 characters, which is sufficient to contain substantive information about management changes rather than a brief announcement. Therefore, the correct classification is MANG with high confidence.
2022-04-07 English
FORM 4 SUBMISSION
Director's Dealing
2022-04-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content discusses an update on the FDA's Emergency Use Authorization for a drug, forward-looking statements, and reaffirmation of previous information. It does not contain comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is not a transcript, proxy, or governance document. The document is a regulatory announcement of a significant event, fitting the category of Regulatory Filings (RNS). The length (8484 characters) and content confirm it is a full Form 8-K report, not just a brief announcement or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-04-05 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-31 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes an announcement about the FDA amending the Emergency Use Authorization for a drug, updates on clinical trials, and forward-looking statements. It does not contain comprehensive financial statements or detailed financial analysis typical of annual or quarterly reports. It also does not fit categories like earnings release, management reports, or audit reports. The document is a regulatory filing reporting a significant event and related company information. Therefore, it fits best under Regulatory Filings (RNS). The document length (8338 characters) and content confirm it is not a brief announcement or a full report but a detailed regulatory current report.
2022-03-25 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.